ReNerve has reported its strongest quarter yet, with sales climbing to $584,000 as the medical device company expands across Asia-Pacific. The growth came alongside a secured funding drawdown, leaving the company with $1.62 million in cash but continued negative operating cash flow.
- Record quarterly sales of $584,000, up 774% year on year
- September monthly sales exceeded $200,000 for the first time
- Initial $1.6 million drawdown from RiverFort secured convertible facility
- NervAlign Nerve Cuff approved in Indonesia and used in first Hong Kong and Malaysia cases
- $1.11 million net operating cash outflow during the quarter
Record sales provide ReNerve with commercial momentum
ReNerve Limited (ASX:RNV) has delivered its strongest sales quarter since launch, reporting $584,000 in quarterly sales for the three months ended 30 September. That was 774% above the corresponding quarter last year and 176% higher than the previous quarter, while September became the first month in which sales exceeded $200,000.
The quarterly result also surpassed the company’s total sales for the 2025/26 financial year. Customer cash receipts were lower at $419,000, a distinction that matters for a company still funding its expansion from external capital as well as product sales.
ReNerve chief executive Dr Julian Chick attributed the performance to multiple product ranges, direct sales staff, 25 US distributors and marketing activity in Asia. The filing does not provide a product-by-product sales breakdown, so the contribution from the NervAlign Nerve Cuff and ReNerve’s other marketed tissue products remains unclear.
Asia-Pacific rollout moves from approvals to clinical use
During the quarter, ReNerve received Indonesian marketing approval for the NervAlign Nerve Cuff and completed its first cases using the product in Hong Kong and Malaysia. The milestones turn regulatory and distribution progress into initial clinical use in those markets, although the announcement does not quantify orders, procedures or revenue generated from the new jurisdictions.
The Hong Kong and Malaysia cases extend the regional rollout described in the company’s first Asia-Pacific surgeries, while Indonesia now provides another market in which ReNerve can work with local partners to introduce the product. Commercial traction in those markets will be a more meaningful test than approvals alone.
RiverFort funding lifts liquidity but adds secured financing
ReNerve drew $1.6 million at face value under a secured convertible note facility with RiverFort Global Opportunities PCC Ltd, receiving approximately $1.361 million after the initial discount, drawdown fee and legal costs. The facility can provide up to $5 million over a three-year availability period, although further drawdowns require mutual agreement and satisfaction of the facility conditions.
The financing is secured by a first-ranking interest over ReNerve’s present and future property, including its entitlement to research and development tax incentive proceeds. The company incurred $271,000 in transaction costs during the quarter, and the filing does not disclose the facility’s interest rate or potential conversion terms.
Operating cash burn remains the measure of durability
ReNerve ended September with $1.621 million in cash and cash equivalents after recording a net operating cash outflow of $1.11 million. Research and development cash expenditure fell to $165,000 from $752,000 in the prior quarter, while advertising and marketing consumed $251,000, staff costs $443,000 and administration and corporate costs $561,000.
Using cash on hand and the $3.4 million of undrawn RiverFort capacity, the Appendix 4C calculates estimated funding availability of 4.5 quarters at the quarter’s operating cash-use rate. That is a financing estimate, not a guarantee of future access: it assumes the remaining facility becomes available and does not resolve whether sales growth will translate into lower cash burn.
RMIT project adds an early-stage research option
ReNerve is also partnering with RMIT on a $499,000 Australian Government-funded project to develop a gel using a patient’s own blood to accelerate nerve regeneration after prostate surgery. The research may have applications across nerve cuffs, wraps, conduits and the Nerve Guide Matrix, but the company expressly cautions that the work remains at the research and development stage and may not produce a regulated or commercial product.
The next quarterly report should show whether the September sales peak was the beginning of a sustained run or a particularly strong period during an early commercial rollout. It should also reveal how much of the RiverFort facility ReNerve needs to draw as it pursues new markets and continues to fund product development.
Bottom Line?
The sales acceleration is material, but the next test is whether customer receipts catch up with reported sales while operating cash use falls without repeated secured funding drawdowns.
Questions in the middle?
- Can ReNerve sustain monthly sales above $200,000 after September’s record result?
- How quickly will Indonesia, Hong Kong and Malaysia contribute meaningful customer receipts?
- What conversion, interest and dilution terms could apply if ReNerve uses more of the RiverFort facility?